Main Logo
ruxolitinib
Adding Navitoclax to Ruxolitinib in Persistent or Progressive Myelofibrosis
Ariel DeMaioPrint | April 12, 2023
This phase II study enrolled 34 adult patients with intermediate- to high-risk myelofibrosis.
Read More

  • 630 Madison Ave.

    Manalapan, NJ 07726

    • About

    Editorial Board

    About Us

    Terms of Use

    Advertising

    Privacy Policy

    Editorial Policy

    Our Network

    MashupMD

    GU Oncology Now

    Cancer Nursing Today

    Urban Health Today

    DocWire News

    Connect

    eNewsletters

    Calendar of Events

    Contact Us

    Contribute

    Formedics logo© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.

    Terms of Use | Privacy Policy |